

# Contents

<b>1 Introduction</b>	
1.1 National Institute for Health and Clinical Excellence (NICE) . . . . .	3
1.2 Attention-Deficit/Hyperactivity Disorder (ADHD) . . . . .	8
<b>2 A Note on Objectives and Methods</b>	
2.1 Objectives . . . . .	23
2.2 Accountability for Reasonableness . . . . .	23
2.3 Methods . . . . .	25
2.4 Limitations . . . . .	26
<b>3 NICE Appraisal Process</b>	
3.1 Scoping . . . . .	29
3.2 Assessment . . . . .	31
3.3 Appraisal . . . . .	35
3.4 Appeal . . . . .	35
3.5 Clinical Guidelines . . . . .	36
<b>4 NICE Appraisal of ADHD Treatments</b>	
4.1 Scope . . . . .	39
4.2 Assessment . . . . .	40
4.3 Appraisal . . . . .	41
4.4 Appeal . . . . .	43
4.5 Clinical Guidelines . . . . .	44
<b>5 NICE Appraisal of ADHD Treatment Options: A Critique</b>	
5.1 Scoping . . . . .	51
5.2 Data Selection for Assessment . . . . .	53
5.2.1 <i>Outcome Measures</i> . . . . .	56
5.2.2 <i>Quality of Life and Utility Estimates</i> . . . . .	59
5.2.3 <i>Selection of Clinical Effectiveness Studies for Economic         Evaluation</i> . . . . .	63
5.3 Efficacy, Effectiveness, and Treatment Compliance . . . . .	72
5.3.1 <i>Internal Versus External Validity of Clinical Trials</i> . . . . .	73
5.3.2 <i>Quantitative Evidence on Treatment Compliance</i> . . . . .	76
5.3.3 <i>Treatment Compliance of Patients with ADHD</i> . . . . .	77

5.4	Data Synthesis Across Endpoints and Studies	82
5.4.1	<i>Data Synthesis Across Endpoints</i>	93
5.4.2	<i>Data Synthesis Across Clinical Studies</i>	95
5.5	Economic Model	98
5.5.1	<i>Literature Review</i>	99
5.5.2	<i>Structure of the Model</i>	100
5.5.3	<i>Economic Model Results</i>	107
5.6	Appraisal and Appeal Process	112
<b>6 Discussion and Implications</b>		
6.1	The Case Study	119
6.1.1	<i>Insights from Clinical Long-Term Studies</i>	123
6.1.2	<i>Insights from Disease-Specific Effectiveness Measures</i>	131
6.2	Case Analysis: Symptoms and Underlying Problems	146
6.2.1	<i>Separation of Clinical and Economic Perspectives</i>	148
6.2.2	<i>High Level of Standardization</i>	149
6.2.3	<i>Technical Quality of Assessment</i>	152
6.2.4	<i>Process-Related Issues</i>	153
6.3	NICE Accountability for Reasonableness	154
6.3.1	<i>Publicity</i>	154
6.3.2	<i>Relevance</i>	157
6.3.3	<i>Appeal</i>	159
6.3.4	<i>Enforcement</i>	160
6.4	NICE Technology Appraisal No. 98 – A Unique Outlier?	161
6.5	Implications for International Health Care Policy-Makers	163
6.5.1	<i>Objectives of Health Care Provision</i>	163
6.5.2	<i>(Almost) Exclusive Reliance on QALYs as Outcome Measure?</i>	165
6.5.3	<i>Technology Appraisal Processes</i>	165
6.5.4	<i>Timing of Technology Appraisals</i>	167
6.5.5	<i>Multidisciplinary Assessment Teams</i>	167
6.5.6	<i>Quality Assurance</i>	168
6.5.7	<i>Implementation</i>	168
<b>7 Which Way Forward?</b>		
7.1	Starting Points	173
7.1.1	<i>Affordability</i>	175
7.1.2	<i>Institutional Context</i>	177
7.2	Objectives, Reconsidered	179
7.2.1	<i>Efficiency</i>	179
7.2.2	<i>Fairness</i>	182
7.3	Research Agenda	184
7.4	Final Note	186
<b>Appendix A Abbreviations and Use of Terminology</b>		189

**Appendix B Critical Gaps of Assessment** ..... 193

- Clinical Effect Measures in ADHD ..... 193
- Impact of Treatment Non-Compliance in ADHD ..... 194
- Pharmacokinetic and Pharmacodynamic Properties of Stimulants ..... 195
- Data Synthesis (Meta-Analysis and Mixed Treatment Comparisons) .. 195
- Comparative Effectiveness and Cost-Effectiveness Analyses ..... 196

**Appendix C Consistency Issues Associated with NICE Assessment** ..... 197

**References** ..... 207

**About the Author** ..... 239

**Index** ..... 241